Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$80.25

1.16 (1.47%)

, INCY

Incyte

$68.15

-0.26 (-0.38%)

20:14
04/23/18
04/23
20:14
04/23/18
20:14

FDA recommends approval of Incyte/Eli Lilly's Baricitinib 2mg, but not 4mg in RA

Eli Lilly (LLY) and Incyte (INCY) announced that the U.S. Food and Drug Administration's Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis for adult patients who have had an inadequate response or intolerance to methotrexate. While the Advisory Committee unanimously supported the efficacy of the 4-mg dose of baricitinib, it did not recommend approval of the 4-mg dose of baricitinib for the proposed indication based on the adequacy of the safety and benefit-risk profiles. Baricitinib 2-mg and 4-mg doses are approved in more than 40 countries, including the member states of the European Union and Japan. For both doses, the Advisory Committee voted to support the assessment that baricitinib's data provide substantial evidence of efficacy. For the 2-mg dose, the Advisory Committee voted in favor of the assessment that baricitinib's safety data adequately support its approval. For the 4-mg dose, the Advisory Committee voted against the assessment that baricitinib's safety data was adequate to support its approval based on the proposed indication.

LLY

Eli Lilly

$80.25

1.16 (1.47%)

INCY

Incyte

$68.15

-0.26 (-0.38%)

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 01

    May

  • 07

    May

  • 21

    May

  • 07

    Jun

  • 12

    Jun

LLY Eli Lilly
$80.25

1.16 (1.47%)

04/23/18
RBCM
04/23/18
NO CHANGE
RBCM
Outperform
Incyte AdCom meeting going more favorably than docs suggested, says RBC Capital
RBC Capital analyst Brian Abrahams said the FDA advisory committee meeting for baricitinib, a rheumatoid arthritis treatment developed by Incyte (INCY) and submitted for review by Eli Lilly (LLY), seems "considerably less negative" than the briefing documents for the meeting had suggested. He sees the tone of the panel and the panelist Q&A suggesting a high likelihood that baricitinib will be approved, with the potential still existing that even a 4mg version could be approved in some form. Abrahams has an Outperform rating and $75 price target on Incyte shares.
04/13/18
04/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: Netflix (NFLX) upgraded to Buy from Hold at Deutsche Bank with analyst Bryan Kraft saying he underestimated the market's willingness to underwrite several years of negative free cash flow to drive growth. 2. Eli Lilly (LLY) upgraded to Market Perform from Underperform at BMO Capital with analyst Alex Arfaei saying he believes that his previously expressed concerns around the downside risks for Humalog, cautious outlook for Vernezio, and uncertainty around Bari are "mostly reflected" in the stock, with more balance in risk-reward going forward. 3. Willis Towers Watson (WLTW) upgraded to Buy from Hold at Sandler O'Neill with analyst Paul Newsome saying he is making a valuation call with the stock down to "both absolute and relative valuations that we have not seen since there were significant concerns about the Willis/Towers Watson merger and the company's ability to generate organic growth." 4. Shaw Communications (SJR) upgraded to Buy from Hold at Canaccord and to Outperform from Sector Perform at Scotiabank. 5. eBay (EBAY) upgraded to Buy from Neutral at Monness Crespi with analyst Jim Chartier saying eBay's structured data initiatives have meaningfully improved the eBay marketplace experience for buyers and sellers, resulting in gross merchandise value inflecting to up 7% in the fourth quarter of 2017 from up 1% in the third quarter of 2016. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/13/18
BMOC
04/13/18
UPGRADE
Target $79
BMOC
Market Perform
Eli Lilly upgraded to Market Perform at BMO Capital on valuation
As reported earlier, BMO Capital analyst Alex Arfaei upgraded Eli Lilly to Market Perform from Underperform and raised his price target to $79 from $74. The analyst believes that his previously expressed concerns around the downside risks for Humalog, cautious outlook for Vernezio, and uncertainty around Bari are "mostly reflected" in the stock, with more balance in risk-reward going forward. While he anticipates 2018 to be volatile as maturing diabetes franchise constrains the company's growth plans, Arfaei also sees some tailwinds for Eli Lilly around continued strong growth of Trulicity, further growth of Taltz, Jardiance, and Basglar, as well as potential divestiture of Elanco.
04/13/18
BMOC
04/13/18
UPGRADE
Target $79
BMOC
Market Perform
Eli Lilly upgraded to Market Perform from Underperform at BMO Capital
BMO Capital analyst Alex Arfaei upgraded Eli Lilly to Market Perform and raised his price target for the shares to $79 from $74.
INCY Incyte
$68.15

-0.26 (-0.38%)

04/20/18
NOMU
04/20/18
NO CHANGE
Target $102
NOMU
Buy
Incyte briefing docs make approval unlikely, says Nomura Instinet
Nomura Instinet analyst Christopher Marai says yesterday's briefing document ahead of the baricitinib FDA panel on April 23 indicates that approval is unlikely. The analyst calls the document "ominous" but keeps a Buy rating on Incyte with a $102 price target.
04/16/18
CANT
04/16/18
NO CHANGE
Target $7
CANT
Neutral
NewLink positive data unlikely to sway investors, says Cantor Fitzgerald
Cantor Fitzgerald analyst Mara Goldstein reiterates a Neutral rating on NewLink Genetics (NLNK) with a $7 price target after the company over the weekend presented data from a Phase I study of indoximod in diffuse intrinsic pontine glioma. While positive, the data are unlikely to "sway investors at this point" given the recent failure of Incyte's (INCY) epacadostat, Goldstein tells investors in a research note.
04/12/18
04/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Incyte (INCY) upgraded to Buy from Neutral at UBS with analyst Carter Gould saying the stock offers an improved risk/reward profile after resetting lower on negative epacadostat Phase 3 data and removal of the drug from analyst models. 2. TechnipFMC (FTI) upgraded to Buy from Neutral at Goldman Sachs with analyst Waqar Syed saying while his 2018/2019 EBITDA estimates are little changed, his 2020 EBITDA estimates have been raised nearly 18% owing to expectations for higher inbound orders in 2019 for the Subsea and Onshore/Offshore segments. 3. Prologis (PLD) upgraded to Buy from Hold at Jefferies with analyst Jonathan Petersen saying he sees the company posting one of the strongest levels of internal growth among the blue-chip real estate investment trusts in 2018. 4. Mylan (MYL) upgraded to Outperform from Market Perform at Leerink with analyst Ami Fadia citing valuation disconnect given the diversified business and catalyst path. 5. Summit Hotel Properties (INN) upgraded to Buy from Underperform at BofA/Merrill with analyst Shaun Kelley citing relative valuation, its potential to outperform peers on the top-line in an accelerating RevPAR environment, and lower relative cost pressure given a lower proportion of labor costs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

ECA

Encana

$13.12

-0.22 (-1.65%)

13:45
05/24/18
05/24
13:45
05/24/18
13:45
Options
Encana call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

13:45
05/24/18
05/24
13:45
05/24/18
13:45
General news
Breaking General news story  »

Philadelphia Federal…

PYPL

PayPal

$82.17

1.1 (1.36%)

13:41
05/24/18
05/24
13:41
05/24/18
13:41
Hot Stocks
FTC gives final approval to PayPal settlement over Venmo claims »

The Federal Trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 30

    May

  • 12

    Jun

SSP

E.W. Scripps

$12.75

-0.1 (-0.78%)

, DIS

Disney

$102.16

-0.74 (-0.72%)

13:36
05/24/18
05/24
13:36
05/24/18
13:36
Hot Stocks
E.W. Scripps renews affiliation pacts with ABC and CBS in several markets »

The E.W. Scripps Company…

SSP

E.W. Scripps

$12.75

-0.1 (-0.78%)

DIS

Disney

$102.16

-0.74 (-0.72%)

CBS

CBS

$50.67

0.16 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

GM

General Motors

$38.42

0.57 (1.51%)

13:31
05/24/18
05/24
13:31
05/24/18
13:31
Technical Analysis
Technical Take: General Motors on upside, positive China Baojun Bloomberg story »

As previously reported,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ACCO

ACCO Brands

$12.95

0.1 (0.78%)

13:29
05/24/18
05/24
13:29
05/24/18
13:29
Conference/Events
ACCO Brands management to meet with KeyBanc »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BECN

Beacon Roofing

$41.97

2.18 (5.48%)

13:26
05/24/18
05/24
13:26
05/24/18
13:26
Conference/Events
Beacon Roofing management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 12

    Jun

  • 21

    Jun

  • 22

    Jun

RUT

Russell 2000 Index

$0.00

(0.00%)

, IWM

iShares Trust Russell 2000 Index Fund

$162.27

0.28 (0.17%)

13:25
05/24/18
05/24
13:25
05/24/18
13:25
Technical Analysis
Technical Take: iShares Trust Russell 2000 Index Fund outperforms »

The iShares Trust Russell…

RUT

Russell 2000 Index

$0.00

(0.00%)

IWM

iShares Trust Russell 2000 Index Fund

$162.27

0.28 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

, VLKAY

Volkswagen

$0.00

(0.00%)

13:25
05/24/18
05/24
13:25
05/24/18
13:25
Periodicals
UAW boss welcomes Trump car-import investigation, Bloomberg says »

United Auto Workers union…

NSANY

Nissan

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

GM

General Motors

$38.39

0.54 (1.43%)

TM

Toyota

$132.52

-2.33 (-1.73%)

F

Ford

$11.64

0.195 (1.70%)

DDAIF

Daimler AG

$0.00

(0.00%)

HMC

Honda

$32.37

-0.65 (-1.97%)

FCAU

Fiat Chrysler

$22.12

-0.345 (-1.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 10

    Sep

13:25
05/24/18
05/24
13:25
05/24/18
13:25
Conference/Events
The Brookings Institution to hold a discussion on trans-atlantic relations »

An expert panel discusses…

GM

General Motors

$38.39

0.54 (1.43%)

13:24
05/24/18
05/24
13:24
05/24/18
13:24
Periodicals
GM is 'killing it' in China with inexpensive model Baojun, Bloomberg says »

General Motors has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CMCSA

Comcast

$31.56

-0.31 (-0.97%)

, CMCSK

Comcast

$0.00

(0.00%)

13:21
05/24/18
05/24
13:21
05/24/18
13:21
Periodicals
Comcast's Fox proposal further tests antitrust officials, Bloomberg says »

Comcast's (CMCSA)…

CMCSA

Comcast

$31.56

-0.31 (-0.97%)

CMCSK

Comcast

$0.00

(0.00%)

FOXA

21st Century Fox

$38.86

0.12 (0.31%)

FOX

21st Century Fox

$38.38

0.15 (0.39%)

T

AT&T

$32.55

0.23 (0.71%)

TWX

Time Warner

$93.95

-0.04 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOLD

Amicus

$16.19

1.04 (6.86%)

13:20
05/24/18
05/24
13:20
05/24/18
13:20
Options
Amicus Therapeutics attracts increased call activity as shares rally »

Amicus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Aug

  • 12

    Sep

13:20
05/24/18
05/24
13:20
05/24/18
13:20
General news
Treasury Action: yields steadied above lows »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
05/24/18
05/24
13:17
05/24/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
05/24/18
05/24
13:16
05/24/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$46.30

1.27 (2.82%)

, HIBB

Hibbett Sports

$28.60

0.25 (0.88%)

13:15
05/24/18
05/24
13:15
05/24/18
13:15
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

FL

Foot Locker

$46.30

1.27 (2.82%)

HIBB

Hibbett Sports

$28.60

0.25 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 25

    May

ROST

Ross Stores

$83.22

0.62 (0.75%)

, ADSK

Autodesk

$138.29

-1.01 (-0.73%)

13:15
05/24/18
05/24
13:15
05/24/18
13:15
Earnings
Notable companies reporting after market close »

Notable companies…

ROST

Ross Stores

$83.22

0.62 (0.75%)

ADSK

Autodesk

$138.29

-1.01 (-0.73%)

DXC

DXC Technology

$99.31

-0.84 (-0.84%)

SPLK

Splunk

$116.29

-0.26 (-0.22%)

GPS

Gap

$33.29

1.32 (4.13%)

VEEV

Veeva

$76.93

0.19 (0.25%)

NTNX

Nutanix

$55.37

-0.875 (-1.56%)

LGF.A

Lionsgate

$23.17

-0.42 (-1.78%)

LGF.B

Lionsgate

$21.90

-0.29 (-1.31%)

DECK

Deckers Brands

$103.58

0.75 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 24

    May

  • 24

    May

  • 24

    May

  • 24

    May

  • 24

    May

  • 31

    May

  • 07

    Jun

  • 14

    Jun

  • 10

    Jul

TSM

TSMC

$39.23

-0.41 (-1.03%)

13:15
05/24/18
05/24
13:15
05/24/18
13:15
Options
Taiwan Semi put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHN

athenahealth

$154.04

0.52 (0.34%)

13:11
05/24/18
05/24
13:11
05/24/18
13:11
Hot Stocks
athenahealth says board undertaking thorough analysis of Elliott's proposal »

athenahealth issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 06

    Jun

13:10
05/24/18
05/24
13:10
05/24/18
13:10
General news
Treasury's $30 B 7-year auction was solid »

Treasury's $30 B…

TWTR

Twitter

$33.44

0.01 (0.03%)

13:05
05/24/18
05/24
13:05
05/24/18
13:05
Hot Stocks
Twitter launches Political Campaigning Policy in U.S. »

"We believe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 27

    Jul

OAS

Oasis Petroleum

$12.76

(0.00%)

13:05
05/24/18
05/24
13:05
05/24/18
13:05
Options
Oasis Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

13:04
05/24/18
05/24
13:04
05/24/18
13:04
General news
7-Yr Note Auction Coupon Rate data reported »

7-Yr Note Auction Coupon…

13:04
05/24/18
05/24
13:04
05/24/18
13:04
General news
7-Yr Note Auction Total Amount data reported »

7-Yr Note Auction Total…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.